[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cd19-negative-b-cell-malignancies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cd19-negative-b-cell-malignancies":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100395548","phase-1-4scar-t-therapy-post-cd19-targeted-immunotherapy-100395548",false,"NCT04430530","4SCAR-T Therapy Post CD19-targeted Immunotherapy","4SCAR-T Therapy After Anti-CD19 Immunotherapy Targeting B Cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n1. Age older than 6 months.\n2. B cell malignancies relapsed after anti-CD19 immunotherapy.\n3. Malignant B cells expressing one or more of the following surface molecules: CD22\u002FCD123\u002FCD38\u002FCD10\u002FCD20.\n4. The KPS score over 80 points, and survival time is more than 1 month.\n5. Greater than Hgb 80 g\u002FL.\n6. No contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. Complications with other active diseases, and difficult to assess patient response.\n2. Bacterial, fungal, or viral infection unable to control.\n3. Living with HIV.\n4. Active HBV and HCV infection.\n5. Pregnant and nursing mothers.\n6. Under systemic steroid use within a week of the treatment.\n7. Judged difficult to cooporate for continued evaluation.","ALL","6 Months","75 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I\u002FII trial enrolling patients from multiple clinical centers.",[28],"CD19 Negative B-cell Malignancies",[30,31,32,33,34,35],"4S CAR-T CD22","4S CAR-T CD123","4S CAR-T CD38","4S CAR-T CD10","4S CAR-T CD20","CD19 Negative B cell leukemiaB-ALL","RECRUITING","2026-06-18",{"date":39,"type":40},"2026-06-23","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":21},"2030-12-31",{"name":46,"class":47},"Shenzhen Geno-Immune Medical Institute","OTHER"]